Human IL-2 as a vaccine adjuvant

Details Human IL-2 as a vaccine adjuvant Human IL-2 as a vaccine adjuvant

1996-10-17

1998-09-01

Ulm, John

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

514 2, 514 8, 514 12, 514885, A61K 3820

Patent

active

058008101

ABSTRACT:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.

REFERENCES:
patent: 3674862 (1972-07-01), Lavender
patent: 4196192 (1980-04-01), Kuo
patent: 4518584 (1985-05-01), Mark et al.
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4780313 (1988-10-01), Koichiro et al.
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4840934 (1989-06-01), Anderson
patent: 5100664 (1992-03-01), Doyle et al.
Colizzi, Inf. & Immunity, 45:25-28 (1984).
Creekmore et al., J. Clinical Oncology, 7(2):276-284 (1989).
Donohue et al., Cancer Research, 44:1380-1386 (1984).
Donohue et al., J. Immunol., 130:2203-2208 (1983).
Homberg et al., J. Immunol., 130:2644-2650 (1983).
Kakumu et al., J. Clin. Lab. Immunol., 26:25-27 (1988).
McFeeters and Nadler, 20th Meeting of Fed. Amer. Soc. for Exp. Biology, Apr. 13-18, (1986), Fed. Proc., 45(3):633 (1986).
Merlizzi et al., Eur. J. Immunopharmac., 7:31-34 (1985).
Mills, J. Immunol., 125:1904-1909 (1980).
Ralph et al., J. Immunol., 133:2442-2445 (1984).
Reed et al., J. Immunol., 133:3333-3337 (1984).
The Shorter Bergey's Manual of Determinative Bacteriology, Eight Edition, John G. Holt, Editor, 1977, pp. 135 & 136, published by the Williams & Wilkins Company, Baltimore, Md., U.S.A. 21202.
Weinberg et al., J. Immunol., 140(1):294-299 (1988).
Ho et al., Vaccine, 10, 209-213 (1992), Human, Guinea Pig, Herpers simplex virus type II glycoprotein D.
Weinberg et al., J. Infect. Diseases, 154, 134-140 (1986), Human, Guinea Pig, Herpes simplex virus type II.
Pillai et al., WO 91/01143, Human, Mouse, Haemophilus type b CRM conjugate, Respiratory syncytial virus E protein.
Mayoral et al., FASEB J., 4, A1035, Abstr 4462 (1990), Human ?, Mouse, E. coli. lipopolysacchoride.
Anderson et al., FASEB J., A318, Abstr 533 (1989), Human ?, Mouse, Tetanus toxoid.
Hinuma et al., FEBS, 288, 138-142 (1991), Human (fusion protein), Mouse, Herpes simplex virus type I glycoprotein D/IL-2 fusion.
Good et al., J. Immunol., 141, 972-977 (1988), Human, Guinea Pig, Herpes simplex virus type I.
Meuer et al., The Lancet, 15-18 (Jan. 7, 1989), Human, Human, Hepatitis B virus.
Frederickson et al., U.S. Patent No. 5,028,421, Chicken, Chicken, Turkey herpes virus.
Weinberg et al., J. Immunol., 140, 294-299 (1988), Human, Guinea pig, Herpes simplex virus type II.
Hughes et al., Vaccine, 10, 226-230 (1992), Bovine, Cattle, Bovine Herpes simplex virus type I glycoprotein subunit.
Wayand et al., J. Clin. Invest., 79, 1756-1763 (1987), Human, Mouse, J5 Enterobacteriaceae antigen.
Kawashima et al., Vet. Immunol. Immunopathol., 22, 345-353 (1989), Human, Pig, Pseudorabies virus subunit.

Affiliated with

Also associated with

Rating

Human IL-2 as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human IL-2 as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human IL-2 as a vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-267256